Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

@article{Julius2004OutcomesIH,
  title={Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial},
  author={Stevo Julius and Sverre E. Kjeldsen and Michael A. Weber and Hans Rudolf Brunner and Steffan Ekman and Lennart Hansson and Tsushung A. Hua and John H. Laragh and Gordon T. Mcinnes and Lada Mitchell and Francis R. Plat and Anthony M. Schork and Beverly A. Smith and Alberto Zanchetti},
  journal={The Lancet},
  year={2004},
  volume={363},
  pages={2022-2031}
}
BACKGROUND The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk. METHODS 15?245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on… Expand

Paper Mentions

Interventional Clinical Trial
This is a double-blinded randomized controlled study assessing the effectiveness of isometric handgrip therapy. Approximately 230 patients who present with a Systolic Blood Pressure… Expand
ConditionsHypertension, Systolic
InterventionDevice
Interventional Clinical Trial
Various guidelines recommended angiotensin converting enzyme (ACE) inhibitors or angiotensin Ⅱ receptor-1 blockers (ARBs) for hypertensive patients with diabetes on the basis of the… Expand
ConditionsHypertension, Type 2 Diabetes Mellitus
InterventionDrug
Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial
TLDR
In no subgroup of patients were there differences in the incidence of the composite cardiac outcome with valsartan and amlodipine-based treatments, despite a greater blood pressure decrease in the amlODipine group. Expand
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial
TLDR
Reaching blood pressure control by 6 months, independent of drug type, was associated with significant benefits for subsequent major outcomes; the blood pressure response after just 1 month of treatment predicted events and survival. Expand
Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular Risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial
TLDR
Codesartan-based and amlodipine-based regimens produced no statistical differences in terms of the primary cardiovascular end point, whereas candesartan prevented new-onset diabetes more effectively than amlODipine. Expand
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk
TLDR
It is noteworthy that the mean BMI of 31 in this cohort is clearly above the accepted diagnostic criterion of obesity and that 60% of patients are diabetic, possibly reflecting secular trends in clinical disease. Expand
Blood Pressure Control with Amlodipine Add-on Therapy in Patients with Hypertension and Diabetes: Results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial
TLDR
Amlodipine is safe and effective when added to quinapril or losartan monotherapy to help lower BP toward therapeutic targets in patients with hypertension and diabetes. Expand
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy
TLDR
Independent of prior cardiovascular history or baseline BP, hypertensive patients requiring combination therapy, which includes a thiazide diuretic for BP control, have a poorer cardiovascular prognosis than those controlled by monotherapy and only a nonsignificantly lower event rate than noncontrolled patients. Expand
Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients
TLDR
Amlodipine safely reduces systolic blood pressure and it may have a beneficial effect on cardiovascular outcomes in hypertensive haemodialysis patients. Expand
Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study.
TLDR
Valsartan add-on treatment to improve blood pressure control prevented more cardiovascular events than conventional non-ARB treatment in high-risk hypertensive patients in Japan. Expand
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial
TLDR
Treatment of hypertensive patients at high cardiovascular risk with the angiotensin-receptor blocker valsartan prevents new-onset type 2 diabetes compared with the metabolically neutral calcium-channel antagonist (CCA) amlodipine, and reduces the risk of developing diabetes mellitus in high-risk hypertensive Patients. Expand
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial
TLDR
It is concluded that valsartan compared with amlodipine reduces the risk of developing diabetes mellitus, particularly in hypertensive patients with the highest susceptibility for development of diabetes. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial
TLDR
Reaching blood pressure control by 6 months, independent of drug type, was associated with significant benefits for subsequent major outcomes; the blood pressure response after just 1 month of treatment predicted events and survival. Expand
Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial
TLDR
The randomized population is now being treated (goal blood pressure < 140/90 mmHg) in adherence with the protocol until at least 1450 patients experience primary cardiac endpoint defined as clinically evident or aborted myocardial infarction, hospitalization for heart failure or death caused by coronary heart disease. Expand
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
TLDR
The data indicate that compared with doxazosin, chlorthalidone reduces the risk of combined CVD events, particularly CHD death/nonfatal MI, in high-risk hypertensive patients. Expand
Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack
TLDR
This blood-pressure-lowering regimen reduced the risk of stroke among both hypertensive and non-hypertensive individuals with a history of stroke or transient ischaemic attack, irrespective of their blood pressure. Expand
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
TLDR
Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan. Expand
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.
TLDR
Of all ongoing mortality and morbidity trials in systemic hypertension, VALUE (Valsartan Antihypertensive Long-term Use Evaluation) is the only one comparing an angiotensin II antagonist (valsartan) with a third-generation calcium channel blocker (amlodipine). Expand
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk
TLDR
The VALUE study is executed in regular clinical settings and 92% of the patients received antihypertensive drugs at baseline and the achieved BP control exceeds values reported in most published large-scale trials. Expand
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
TLDR
Old and new antihypertensive drugs were similar in prevention of cardiovascular mortality or major events, and decrease in blood pressure was of major importance for the Prevention of cardiovascular events. Expand
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
TLDR
Nifedipine once daily and co-amilozide were equally effective in preventing overall cardiovascular or cerebrovascular complications in high-risk patients with hypertension. Expand
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
TLDR
Captopril and conventional treatment did not differ in efficacy in preventing cardiovascular morbidity and mortality and the difference in stroke risk was probably due to the lower levels of blood pressure obtained initially in previously treated patients randomised to conventional therapy. Expand
...
1
2
3
4
5
...